tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

ADIL Stock Latest News

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
Press ReleasesAdial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
6d ago
ADIL
Adial Pharmaceuticals engages The Keswick Group
The FlyAdial Pharmaceuticals engages The Keswick Group
6d ago
ADIL
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
Press ReleasesAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
19d ago
ADIL
ADIL Soars after Positive Regulatory Update
Market NewsADIL Soars after Positive Regulatory Update
20d ago
ADIL
Adial Pharmaceuticals to pursue FDA approval for AD04
The FlyAdial Pharmaceuticals to pursue FDA approval for AD04
21d ago
ADIL
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
Press ReleasesAdial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
21d ago
ADIL
Adial Pharmaceuticals Schedules Business Update Conference Call
Press ReleasesAdial Pharmaceuticals Schedules Business Update Conference Call
25d ago
ADIL
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
Press ReleasesAdial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
28d ago
ADIL
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
Press ReleasesAdial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
1M ago
ADIL
Adial Pharmaceuticals prices $750K offering at 41c per share
The FlyAdial Pharmaceuticals prices $750K offering at 41c per share
1M ago
ADIL
Adial confirms scheduled meetings with regulatory authorities to discuss AD04
The FlyAdial confirms scheduled meetings with regulatory authorities to discuss AD04
1M ago
ADIL
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
2M ago
EQ
ADIL
Adial enters into option agreement for sale of Purnovate assets to Adenomed
The FlyAdial enters into option agreement for sale of Purnovate assets to Adenomed
2M ago
ADIL
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
Press ReleasesAdial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
2M ago
ADIL
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Press ReleasesAdial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
4M ago
ADIL
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
Press ReleasesAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
6M ago
ADIL
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
Press ReleasesAdial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
7M ago
ADIL
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Press ReleasesAdial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
7M ago
ADIL
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Press ReleasesAdial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
8M ago
ADIL
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
Press ReleasesAdial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
9M ago
ADIL
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
Press ReleasesAdial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
9M ago
ADIL
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
Press ReleasesAdial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
10M ago
ADIL
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.